About us
Our History
Transforming the Understanding and Treatment of Neurodegeneration
ImmunoBrain Checkpoint is a clinical-stage biopharmaceutical company committed to developing innovative immunotherapies for neurological disorders.
1999
Protective Autoimmunity
Prof. Michal Schwartz suggests the concept of “Protective Autoimmunity”,
and that peripheral immune cells play a critical role in shaping brain function.
![](https://immunobrain.com/wp-content/uploads/2023/12/Our-History_VisualsNew1.jpg)
1999
2015
ImmunoBrain Checkpoint is founded
ImmunoBrain Checkpoint, Inc. incorporates and enters a Research and
License Agreement with Yeda, the commercialization company of the
Weizmann Institute of Science to develop and commercialize the technology
that emerges out of the Schwartz lab.
![](https://immunobrain.com/wp-content/uploads/2023/12/Our-History_Visuals2.jpg)
2015
2016
Immune checkpoint blockade
First evidence that immune checkpoint therapeutic approach can be utilized
for treating Alzheimer's disease (Baruch et al., 2016, Nature Medicine).
![](https://immunobrain.com/wp-content/uploads/2023/12/Our-History_VisualsNew12.jpg)
2016
2017
Lead selection and optimization
ImmunoBrain Checkpoint licenses the rights to develop and commercialize a
novel, fully human anti-PD-L1 antibody from Kymab (now a Sanofi company).
![](https://immunobrain.com/wp-content/uploads/2023/12/Our-History_Visuals4.jpg)
2017
2022
Regulatory approvals
Regulatory approvals received to initiate clinical study in Europe.
![](https://immunobrain.com/wp-content/uploads/2023/12/Our-History_Visuals5.jpg)
2022
2023
IBC-01-01 clinical study
ImmunoBrain Checkpoint initiates IBC-01-01 Trial, a randomized, double-blind,
placebo-controlled, first-in-human Phase Ib clinical trial in persons with
early Alzheimer’s disease.
![](https://immunobrain.com/wp-content/uploads/2023/12/Our-History_Visuals6.jpg)
2023